Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Study of New Antibiotic Regimen for the Treatment of Uncomplicated Cellulitis in Emergency Department Patients

N/ACompletedNCT00676130
Brigham and Women's Hospital153 enrolled

Overview

The primary aim of this study is to quantify the effectiveness of Bactrim as additional therapy for the treatment of uncomplicated cellulitis in adults, by comparing: standard therapy plus Bactrim, versus standard therapy plus placebo. The primary hypothesis of this study is that, in light of increasing CA-MRSA prevalence, subjects treated with standard therapy plus Bactrim will have higher cure rates than those treated with standard therapy plus placebo.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

153

Conditions

Cellulitis

Interventions

trimethoprim-sulfamethoxazoleDRUG

Weight-based dosing in capsule or suspension form according to the following scale: 15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily 20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily 25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily 29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily 60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily 60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily \> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily

CephalexinDRUG

Weight-based dosing in capsule or suspension form according to the following scale: 15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily 20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily 25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily 29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily 60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily \> 80 kg (176 lbs): Cephalexin 1000 mg four times daily

Eligibility

Sex: ALLMin age: 12 Months
Medical Language ↔ Plain English
Inclusion Criteria * Must have cellulitis as defined here: 1. Definition A (preferred definition): Recent onset of soft tissue erythema, considered by the treating clinician to be bacterial in origin, and associated with signs of infection that include at least two of the following: pain, swelling, warmth, fever, lymphangitis, induration, or ulceration. 2. Definition B (ONLY for darkly-pigmented subjects who cannot use Definition A): Recent onset of soft tissue color change, pain, or swelling, considered by the treating clinician to be bacterial in origin, and at least one of the following: warmth, fever, induration, or ulceration * Clinical (non-research) attending physician agrees with treatment with cephalexin until 3 days after all symptoms gone, using our weight-based dosing * Responsible clinical attending physician comfortable with adding trimethoprim-sulfamethoxazole vs. placebo to the above * Subject understands the study and signs written informed consent. * Subject agrees to drink at least 1 liter of fluid per day. * Subject will commit to all follow-up appointments Exclusion Criteria: * Age \< 12 months or weight \<15 kg * Current skin infection has already been treated * Allergy to sulfa drugs * History of severe allergic reaction to penicillin (defined as anaphylactoid reaction, angioedema, bronchospasm) * Current use of any antibiotic (other than topicals) * Diabetes mellitus * Cellulitis complicated by underlying peripheral vascular disease * Renal insufficiency, defined as patient report, clinical suspicion, or creatinine\>1.3 or EGFR\<60 on the last-available set of chemistry results in our computer system * Hospital admission required * Presence of \> 1 cc of purulent discharge at any time * Cellulitis involving an indwelling vascular, enteric, or urinary catheter * Immunocompromise of any etiology * Pregnancy * Breast feeding * Facial cellulitis (infection is above the clavicles) * Cellulitis associated with marine or freshwater injury, or animal or human bite. (Insect bites not excluded.) * History of glucose-6-phosphate dehydrogenase deficiency * Taking coumadin (warfarin), methotrexate, cisapride, phenytoin (dilantin), digoxin, or dofetilide * Known megaloblastic anemia due to folate deficiency.

Locations (3)

Massachusetts General Hospital

Boston, Massachusetts, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Children's Hospital Boston

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Relative Efficacy

Proportion of subjects in each arm with successful treatment. Treatment success was assessed by physician examination at 12 +/- 2 days. Non-success was defined as subsequent hospitalization, change in antibiotics, surgical or needle drainage of an abscess, or recurrence of infection within 30 days. Cure was defined as resolution of all symptoms other than mild residual erythema or edema. We confirmed the determination of cure by telephone interview and medical record review at 30 +/- 2 days.

Time frame: 12 +/- 2 days; 30 +/- 2 days

Secondary Outcomes

Progression to Abscess

Proportion of subjects in each arm with progression from cellulitis to abscess.

Time frame: 12 +/- 2 days, 30 days +/- 2 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.